Equities

10X Genomics Inc

10X Genomics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.29
  • Today's Change-0.03 / -0.23%
  • Shares traded1.63m
  • 1 Year change-68.96%
  • Beta1.8180
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

  • Revenue in USD (TTM)629.74m
  • Net income in USD-182.55m
  • Incorporated2012
  • Employees1.26k
  • Location
    10X Genomics Inc6230 Stoneridge Mall RoadPLEASANTON 94588United StatesUSA
  • Phone+1 (925) 401-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.10xgenomics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Establishment Labs Holdings Inc153.07m-70.61m1.19bn933.00--36.43--7.78-2.58-2.585.571.170.55340.79162.51168,580.40-25.53-33.22-31.21-41.1265.0864.73-46.13-43.192.29-4.510.856--2.1321.96-4.38--69.16--
STAAR Surgical Co341.22m21.78m1.31bn1.06k60.783.0647.443.850.43810.43816.908.690.67632.033.15323,128.804.326.774.927.9078.7376.896.389.165.38--0.00020.0013.3721.07-46.1833.8551.95--
Adapthealth Corp3.26bn-217.76m1.33bn10.70k--0.87768.070.4079-1.64-1.6424.2311.270.709621.158.45304,912.50-4.57-4.34-5.14-4.8919.0318.28-6.44-6.470.99512.290.5757--7.73---1,169.99------
Evolent Health Inc2.46bn-104.23m1.35bn4.70k--1.2892.720.5482-0.9129-0.912921.5510.660.953--6.14524,309.40-2.79-9.60-3.58-12.5915.9624.50-2.93-13.66---0.55950.3285--45.2625.65-660.71---6.18--
Myriad Genetics, Inc.823.60m-116.00m1.38bn2.70k--1.88--1.67-1.30-1.309.218.040.73859.916.84305,037.00-10.40---12.43--69.15---14.08--1.73-105.000.0506--11.03---135.09------
Inmode Ltd423.75m153.67m1.41bn581.0010.012.079.143.331.851.855.048.920.52391.5810.15729,339.1019.0031.3220.7735.6481.6484.4636.2639.659.91--0.000.008.3237.4922.5454.6513.10--
Alphatec Holdings Inc572.74m-177.87m1.45bn839.00------2.53-1.27-1.274.080.15460.80891.117.73682,644.80-25.12-30.97-32.00-39.4769.4766.02-31.06-46.221.15-3.660.9596--37.4539.38-23.36--67.92--
10X Genomics Inc629.74m-182.55m1.61bn1.26k--2.23--2.55-1.53-1.535.265.970.66772.406.72500,193.00-19.36-25.52-21.99-29.0566.6375.88-28.99-48.534.12--0.00--19.8133.43-53.67--49.15--
AtriCure Inc447.57m-38.92m1.74bn1.20k--3.74--3.89-0.8322-0.83229.569.540.73651.638.41372,977.50-6.40-3.72-7.35-4.1074.7974.36-8.70-7.642.59-13.760.1194--20.8414.6434.49--46.56--
Integra Lifesciences Holdings Corp1.56bn-6.54m1.77bn3.95k--1.1713.891.13-0.0881-0.088120.2219.730.4011.595.99396,583.90-0.16773.33-0.20023.6859.2963.67-0.41827.990.72614.050.54280.00-1.030.9219-62.482.19-2.97--
Patterson Companies, Inc.6.53bn168.41m1.79bn7.60k11.081.886.930.27361.831.8371.2210.802.275.8615.35859,640.705.841.1310.151.8121.0320.982.570.51570.67237.910.4474304.751.503.34-10.4218.102.170.00
Rxsight Inc128.29m-30.69m1.82bn374.00--6.54--14.15-0.8194-0.81943.406.890.52121.996.32343,029.40-12.47---13.62--68.44---23.92--11.71--0.0005--81.77--27.19------
Novocure Ltd577.74m-149.78m1.85bn1.45k--5.12--3.20-1.39-1.395.373.340.48793.598.74397,617.30-12.65-7.74-20.29-8.9576.4277.22-25.93-14.691.44--0.6446---5.3015.47-123.75--32.19--
Tandem Diabetes Care Inc854.35m-126.78m2.02bn2.40k--8.49--2.36-1.94-1.9413.083.620.90042.908.23355,979.60-13.36-10.08-17.47-12.2349.7951.77-14.84-11.592.32--0.5945---6.6832.39-135.33--76.81--
Omnicell Inc1.06bn-17.69m2.03bn3.66k--1.6630.571.91-0.3917-0.391723.1726.590.47045.904.06291,563.30-0.78171.73-1.112.2541.4446.69-1.662.920.9529--0.31720.00-11.487.82-460.68--0.235--
Data as of Nov 21 2024. Currency figures normalised to 10X Genomics Inc's reporting currency: US Dollar USD

Institutional shareholders

54.31%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 202411.36m10.62%
The Vanguard Group, Inc.as of 30 Sep 202410.82m10.11%
ARK Investment Management LLCas of 30 Sep 202410.75m10.05%
Nikko Asset Management Americas, Inc.as of 30 Sep 20246.37m5.96%
BlackRock Fund Advisorsas of 30 Sep 20245.20m4.86%
Morgan Stanley Investment Management, Inc.as of 30 Sep 20244.35m4.07%
Citadel Advisors LLCas of 30 Sep 20242.51m2.35%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 20242.38m2.23%
Brown Capital Management LLCas of 30 Sep 20242.20m2.05%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20242.16m2.02%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.